|
AstraZeneca today announced that the U.S. FDA has approved Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure in adults
AstraZeneca reported positive phase 3 trial results of Brilinta (ticagrelor) plus aspirin, which reduced the relative risk of cardiovascular events
Motivational text messaging may be the key to improving blood sugar control in patients with diabetes and coronary heart disease, according to a new
Exercise. Improve your diet. Lose weight. You’ve probably heard the mantra over and over again. People living with diabetes know that along
Following a Mediterranean diet, which includes eating plenty of fruits, vegetables, beans, and good fats, may improve brain function, according to a
Researchers have demonstrated that the recently developed antidiabetic drug empagliflozin can treat and reverse the progression of heart failure in
The commonly used diabetes drug metformin could reverse the harmful thickening of the heart muscle that leads to cardiovascular disease, according to
While investigating why cholesterol-lowering drugs called statins cause negative side effects such as blurred vision, short-term memory loss or
AstraZeneca’s drug Brilinta® met primary endpoints in Phase 3 trials, the company reported on Monday. The trials showed that Brilinta
Two drugs commonly prescribed to treat type 2 diabetes carry a high risk of cardiovascular events such as heart attack, stroke, heart failure or
Get a little dLife delivered to your inbox every week.
Leave this field empty if you’re human: